For in vivo experiments, we compared the antitumor activity of sacituzumab govitecan (hRS7-CL2A-SN-38), control ADC (h679-CL2A-SN-38), naked hRS7 IgG and normal saline (four mice in each group) against Trop-2 positive cervical cancer xenografts (CVX8). Here, TACSTD2 is linked to cervical cancer.